SEATTLE – Omeros (NASDAQ:) Corporation (NASDAQ:OMER), a biopharmaceutical company, has reported significant progress toward the resubmission of its biologics license application (BLA) for narsoplimab. The drug is designed to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a rare complication of stem cell transplantation. The company has received feedback from the U.S. Food and Drug Administration (FDA) on its revised statistical analysis plan (SAP) and is moving forward with no known impediments to resubmitting the BLA.
The FDA had previously provided minor feedback on the SAP for the primary efficacy endpoint during a September 2024 meeting. Following the FDA’s recommendations, Omeros revised the SAP and has now received a response from the FDA with additional, acceptable recommendations. An independent statistical group will incorporate these recommendations into the final SAP and conduct the prespecified efficacy analyses.
The company plans to publicly share the outcome of the primary analysis and, subsequently, additional analyses as they are completed. This will follow the validation of results by the independent group. Omeros has stated its intention to finalize and resubmit the BLA as soon as the analytical results are supportive.
Omeros specializes in developing therapeutics for immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Narsoplimab, Omeros’ lead MASP-2 inhibitor, targets the lectin pathway of complement and is pending FDA review for TA-TMA treatment.
The company is also advancing other drug candidates, including OMS1029 and OMS906, through clinical trials for various indications. Omeros’ financial and operational prospects, including the initiation or continuation of clinical trials and the availability of data, are subject to various risks and uncertainties, as outlined in their regulatory filings.
This update is based on a press release statement from Omeros Corporation. The company is preparing to take the next steps in the regulatory process, aiming to bring narsoplimab closer to potential FDA approval and availability for patients with TA-TMA.
In other recent news, Omeros Corporation reported a decrease in its net loss for the third quarter of 2024, which stood at $32.2 million compared to the previous quarter’s loss of $56 million. The company’s cash reserves were reported at $123.2 million. A deal with DRI Healthcare over OMIDRIA royalties is set to bring potential milestone payments, further improving the company’s financial standing.
Omeros is also making notable strides in its drug development programs. The company is preparing to resubmit its Biologics License Application for narsoplimab and is planning to initiate Phase 3 trials for zaltenibart, a promising drug candidate, in early 2025.
The company’s financial outlook for the fourth quarter includes stable operating costs and an expected income from discontinued operations in the range of $7 million to $8 million. These recent developments reflect Omeros’ ongoing efforts to improve its financial health and advance its key drug programs.
InvestingPro Insights
As Omeros Corporation (NASDAQ:OMER) progresses towards resubmitting its biologics license application for narsoplimab, investors are closely watching the company’s financial health and market performance. According to InvestingPro data, Omeros has a market capitalization of $348.51 million, reflecting the market’s current valuation of the company’s potential.
Despite the promising developments in its regulatory pathway, Omeros faces financial challenges. An InvestingPro Tip indicates that the company is “quickly burning through cash,” which is a critical factor for investors to consider given the capital-intensive nature of drug development and the regulatory process. This cash burn rate underscores the importance of the narsoplimab BLA resubmission for the company’s future.
On a positive note, Omeros has seen strong market performance recently. The company’s stock has shown a remarkable 258.93% price total return over the past year, and a 47.07% return in the last month alone. This upward trend suggests that investors are optimistic about the company’s prospects, possibly in anticipation of positive outcomes from the narsoplimab regulatory process.
However, it’s important to note that Omeros is not currently profitable, with a negative gross profit of $69.78 million in the last twelve months as of Q3 2023. This aligns with another InvestingPro Tip stating that “analysts do not anticipate the company will be profitable this year.” This financial situation is not uncommon for biopharmaceutical companies in the development stage, but it emphasizes the significance of achieving regulatory milestones for potential future revenue streams.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 13 more tips available for Omeros Corporation. These tips can provide a deeper understanding of the company’s financial position and market outlook as it navigates the critical stages of drug approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.